Study of the Effect of Pneumococcal Conjugate Vaccine (PCV) on Immunogenicity of Pentacel™

Inclusion Criteria : * Healthy infants 2 months (≥ 42 days and ≤ 89 days) of age. * Infants with at least 36 weeks of gestation at delivery. * Must have received 1 dose of Hepatitis B vaccine (with that dose at least 15 days before the administration of study vaccines). * Able to attend the scheduled visits and to comply with the study procedures. * Parent or legal guardian willing to take rectal temperatures during the infant series. * Parent or legal guardian has access to a telephone. * Signed informed consent from parent or legal guardian obtained before the 1st study intervention. * Able to obtain at least 1.5 mL of blood sample prior to Dose 1. Exclusion Criteria : * Clinically significant findings on review of systems (determined by investigator or sub-investigator to be sufficient for exclusion). * Known or suspected hypersensitivity to any component of the study vaccine to be administered. * Known or suspected impairment of immunologic function or receipt of immunosuppressive therapy or immunoglobulin since birth. * Known Human Immunodeficiency Virus (HIV)-positive mother or child. * Personal or immediate family history of congenital immune deficiency. * Developmental delay or neurologic disorder. * Chronic medical, congenital, or developmental disease. * Participation in any other clinical trial. * Any condition which, in the opinion of the investigator, would interfere with the evaluation of the vaccine or pose a health risk to the subject. * Prior history of having received any Acellular Pertussis- (DTaP) or Whole Cell Pertussis- (DTwP) based combination vaccines, Haemophilus influenzae Type b (Hib)-conjugate, Poliovirus, or Pneumococcal conjugate vaccines.